Finance

Roʻyxatlar
TRVN:OTCMKTS
Trevena Inc
0,066 US$
0,00%
(0,00) 1K
12-okt, 14:57:26 (GMT-4)  ·   USD
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
TRVN tikeri uchun statistika yaratilmoqda...
Bozor kapitali
57,01 ming
Oʻrtacha hajm
210,00
Hajmi
9,00
52 haftalik eng yuqori
1,50 US$
52 haftalik eng past
0,00 US$
Beta
1,07
Muomaladagi aksiyalar
864,00 ming
Xodimlar soni
23
Bozor kapitali
57,01 ming
Oʻrtacha hajm
210,00
Hajmi
9,00
52 haftalik eng yuqori
1,50 US$
52 haftalik eng past
0,00 US$
Beta
1,07
Muomaladagi aksiyalar
864,00 ming
Xodimlar soni
23
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week. Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Trevena Inc haqida
CEO-
Xodimlar soni23
Asos solingan2007
Bosh ofislarAtlanta, Jorjiya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-sayttrevena.com
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
dek, 2023
mar, 2024
iyn, 2024
sen, 2024
Daromad
-82,00 ming
20,00 ming
325,00 ming
283,00 ming
Sotilgan mahsulotning tannarxi
-
-
-
114,00 ming
Daromad narxi
-
-
-
114,00 ming
Tadqiqot va ishlanmalarga xarajatlar
-
-
-
1,87 mln
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
-
-
-
3,88 mln
Operatsion xarajatlar
-
-
-
5,75 mln
Jami operatsion xarajatlar
-
-
-
5,86 mln
Operatsion daromad
-
-
-
-5,58 mln
Boshqa nooperatsion daromad
-
-
-
479,00 ming
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
-
-
-
-4,91 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
-
-
-
-4,91 mln
Daromad soligʻi boʻyicha xarajat
-
-
-
30,00 ming
Amaldagi soliq stavkasi
-
-
-
-0,61%
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
-
-
-
-4,94 mln
Sof foyda marjasi
-
-
-
-1 745,23%
Har bir aksiya foydasi
-
-
-
-
Foizlar va investitsiyalardan olingan daromadlar
-
-
-
190,00 ming
Foizlarni toʻlash xarajatlari
-
-
-
-1,00 ming
Foizlarni toʻlash boʻyicha sof xarajatlar
-
-
-
189,00 ming
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
-
-
-
-5,48 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
-
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari